Research programme: personalised multiple myeloma therapeutics - MMRF/Onyx
Latest Information Update: 16 Jul 2016
At a glance
- Originator Multiple Myeloma Research Foundation; Onyx Pharmaceuticals
- Developer Onyx Pharmaceuticals
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Multiple-myeloma in USA
- 01 Oct 2013 Onyx Pharmaceuticals has been acquired by Amgen
- 14 Dec 2011 Early research in Multiple myeloma in USA (unspecified route)